General information

The 18-ICML will take place from June 17 to June 21, 2025.

Scientific Advisory Board


The Scientific Advisory Board is made up of lymphoma experts and specialists from all over the world. Their role is fundamental in the development of the ICML Scientific Programme, assisting the Organising Committee to ensure not only the impartiality of the abstract evaluation, but also the multiplicity of approaches and skills.
They contribute to the choice of topics and speakers and rate the submitted abstracts. During the Conference itself they also play a part by introducing special lectures and moderating the sessions.


Members of 18-ICML Scientific Advisory Board


Ranjana H. Advani, Palo Alto, CA, US

James O. Armitage, Omaha, NE, US – Chairman

Elias Campo, Barcelona, ES

Bruce D. Cheson, Bethesda, MD, US

Riccardo Dalla-Favera, New York, NY, US

Matthew S. Davids, Boston, MA, US

Stephan Dirnhofer, Basel, CH

Martin Dreyling, Munich, DE

Manuela Eicher, Lausanne, CH

Andrew M. Evens, New Brunswick, NJ, US

Jonathan W. Friedberg, Rochester, NY, US

Mary K. Gospodarowicz, Toronto, ON, CA

Peter W.M. Johnson, Southampton, UK

Brad S. Kahl, St. Louis, MO, US

Won Seog Kim, Seoul, KR

Marco Ladetto, Alessandria, IT

T. Andrew Lister, London, UK

Stefano Luminari, Reggio Emilia, IT


Ari M. Melnick, New York, NY, US

Bertrand Nadel, Marseilles, FR

Urban Novak, Bern, CH

Grzegorz S. Nowakowski, Rochester, MN, US

Koichi Ohshima, Kurume, JP

Astrid Pavlovsky, Buenos Aires, AR

Leticia Quintanilla de Fend, Tübingen, DE

Gilles Salles, New York, NY, US

Kerry J. Savage, Vancouver, BC, CA

John F. Seymour, Melbourne, AU

Sonali M. Smith, Chicago, IL, US

Lena Specht, Copenhagen, DK

Catherine Thieblemont, Paris, FR

Marek Trneny, Prague, CZ

Wilhelm Wössmann, Hamburg, DE

Thorsten Zenz, Zurich, CH

Weili Zhao, Shanghai, CN

Pier Luigi Zinzani, Bologna, IT

Participant profile and conference objectives


The conference objectives and learning outcomes are:

  • Acquaintance with the latest advances in basic science regarding lymphoma;
  • Learning about the latest results of translational research into lymphoma;
  • Information on the most recent data from clinical studies;
  • Fostering discussion and sharing of ideas among attendees about innovations in the field of lymphoma;
  • Spreading evidence-based knowledge of primary clinical relevance.

The content of the Programme aims to:

  • Provide information that is useful to the work of participants and relevant to practice techniques;
  • Present well-balanced data supported by adequate evidence;
  • Allow time for discussion and questions.

The 17-ICML Congress (13-17 June 2023) gathered around 4000 physicians from all over the world in Lugano: haematologists, clinical oncologists, radiation oncologists, paediatricians, pathologists and leading researchers involved in the study and treatment of lymphoid neoplasms.


International cooperations


The ICML Organising Committee is proud to cooperate with the following international associations, societies and groups:

American Association for Cancer Research (AACR),
European Oncology Nursing Society (EONS),
European Society for Medical Oncology (ESMO),
European School of Oncology Foundation (ESOF),
European Society for Paediatric Oncology (SIOPE) Nursing Group,
Haematology Nurses & Healthcare Professionals Group,
International Lymphoma Radiation Oncology Group (ILROG),
Swiss Oncology Nursing Society (OPS/SOS),
Union for China Lymphoma Investigators (UCLI),
Lymphoma Canine Network.

Their collaboration in jointly defining several of the sessions and workshops is essential to the achievement of ICML objectives and learning outcomes.

ESO Certificate of Competence in Lymphoma


The 18-ICML Programme will be part of the seventh edition of the Certificate of Competence in Lymphoma (CCL), a 14-month European Credit Transfer and Accumulation System (ECTS) programme developed by the European School of Oncology (ESO) and academically recognised by Ulm University.
The purpose of the Certificate of Competence is to provide a curriculum of studies to advance knowledge and science in the management of lymphoma patients.

For further information, please contact the ESO Bellinzona office.